| Literature DB >> 15726104 |
S P Hu1, N E Day, D R Li, R N Luben, K L Cai, T Ou-Yang, B Li, X Z Lu, B A J Ponder.
Abstract
We typed 247 cases of nasopharyngeal carcinoma (NPC), a disease predominantly of the southern Chinese, and 274 controls from the Chao Shan region of China's Guangdong province for HLA A and B. Besides confirming the established associations with A2, A33, B46 and B58 (positive associations) and A11 (negative association), the results demonstrated a number of rarer alleles with strong negative association with NPC. Our data, combined with those from the previous studies in Southern Chinese, displayed the protective effects for A31 (odds ratio (OR)=0.0; 95% confidence interval (CI)=0-0.11), B13 (OR=0.50; 95% CI=0.35-0.69), B27 (OR=0.49; 95% CI=0.25-0.92), B39 (OR=0.18; 95% CI=0.06-0.48) and B55 (OR=0.32; 95% CI=0.14-0.68), the ORs comparing individuals with or without each allele. Other ethnic groups do not display such large HLA-associated variation in NPC risk. We show that a linked NPC gene with dominant mode of action could not generate such large protective effects. The results provide strong supporting evidence for the existence of a southern Chinese specific, recessive NPC gene closely linked to the HLA region as a major determinant of the Chinese risk for the disease.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15726104 PMCID: PMC2361898 DOI: 10.1038/sj.bjc.6602347
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Frequency distribution of HLA-A and HLA-B genes in NPC patients and controls
|
|
|
|
| |
|---|---|---|---|---|
|
| ||||
| A1 | 0.008 | 0.007 | 1.11 | 0.01 |
| A2 | 0.643 | 0.529 | 1.61 | 7.00 |
| A3 | 0.004 | 0.010 | 0.37 | 0.81 |
| A11 | 0.380 | 0.572 | 0.46 | 19.23 |
| A24 | 0.291 | 0.321 | 0.87 | 0.54 |
| A26 | 0.068 | 0.054 | 1.28 | 0.45 |
| A29 | 0.004 | 0.003 | 1.11 | 0.01 |
| A30 | 0.036 | 0.032 | 1.11 | 0.05 |
| A31 | 0.000 | 0.040 | 0.00 | 10.11 |
| A32 | 0.024 | 0.003 | 6.80 | 4.17 |
| A33 | 0.246 | 0.200 | 1.31 | 1.60 |
| A68 | 0.008 | 0.003 | 2.23 | 0.45 |
| A80 | 0.004 | 0.000 | 0.00 | 1.11 |
|
| ||||
| B7 | 0.000 | 0.003 | 0.00 | 0.90 |
| B8 | 0.000 | 0.003 | 0.00 | 0.90 |
| B13 | 0.076 | 0.178 | 0.38 | 11.87 |
| B15 | 0.024 | 0.018 | 1.34 | 0.23 |
| B18 | 0.000 | 0.007 | 0.00 | 1.81 |
| B27 | 0.024 | 0.069 | 0.33 | 5.76 |
| B35 | 0.052 | 0.065 | 0.79 | 0.40 |
| B37 | 0.008 | 0.007 | 1.11 | 0.01 |
| B38 | 0.153 | 0.109 | 1.48 | 2.25 |
| B39 | 0.004 | 0.043 | 0.09 | 8.42 |
| B44 | 0.012 | 0.003 | 3.36 | 1.23 |
| B46 | 0.344 | 0.226 | 1.79 | 8.89 |
| B48 | 0.024 | 0.018 | 1.34 | 0.23 |
| B51 | 0.113 | 0.105 | 1.08 | 0.08 |
| B52 | 0.016 | 0.025 | 0.63 | 0.55 |
| B53 | 0.004 | 0.000 | 0.00 | 1.11 |
| B54 | 0.060 | 0.051 | 1.20 | 0.23 |
| B55 | 0.016 | 0.058 | 0.27 | 6.25 |
| B56 | 0.024 | 0.018 | 1.34 | 0.23 |
| B57 | 0.004 | 0.003 | 1.11 | 0.01 |
| B58 | 0.246 | 0.222 | 1.15 | 0.43 |
| B60 | 0.336 | 0.368 | 0.87 | 0.60 |
| B61 | 0.080 | 0.032 | 2.59 | 5.71 |
| B62 | 0.105 | 0.098 | 1.08 | 0.06 |
| B67 | 0.008 | 0.003 | 2.23 | 0.45 |
| B71 | 0.000 | 0.007 | 0.00 | 1.81 |
| B72 | 0.012 | 0.018 | 0.66 | 0.32 |
| B75 | 0.068 | 0.087 | 0.77 | 0.63 |
| B76 | 0.008 | 0.014 | 0.55 | 0.48 |
| B81 | 0.000 | 0.003 | 0.00 | 0.90 |
P<0.001,
P<0.005,
P<0.01,
P<0.05.
Odds ratios for selected HLA A and B alleles, combining data from this study and two previous studies
|
|
|
|
|
|
|---|---|---|---|---|
| A2 | 1.81 | 15.31 | 0.0001 | 1.33–2.48 |
| A11 | 0.55 | 32.81 | 0.0000 | 0.45–0.68 |
| A31 | 0.00 | 33.76 | 0.0000 | 0.00–0.11 |
| A33 | 1.37 | 4.58 | 0.0323 | 1.02–1.85 |
| B13 | 0.50 | 18.24 | 0.0000 | 0.35–0.69 |
| B27 | 0.49 | 5.51 | 0.0189 | 0.25–0.92 |
| B38 | 1.73 | 6.04 | 0.0140 | 1.09–2.76 |
| B39 | 0.18 | 15.31 | 0.0001 | 0.06–0.48 |
| B46 | 1.69 | 21.99 | 0.0000 | 1.35–2.13 |
| B55 | 0.32 | 10.55 | 0.0012 | 0.14–0.68 |
| B58 | 1.30 | 4.57 | 0.0324 | 1.01–1.68 |
Based on this study and Lu et al (2003).
Based on this study, Lu et al (2003) and both phases of Hildesheim et al (2002).
Based on this study, Lu et al (2003) and Phase 1 of Hildesheim et al (2002).
Figure 1Distributon among cases and controls of a score calculated for each individual as the sum of the log OR (from Table 2) for each allele of that individual.